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ABSTRACT
Ovarian cancer can be intraoperatively staged only. This staging is based on intraoperative findings and his-
tological postoperative result. In early-staged ovarian cancer, it is essential to exclude a higher FIGO stage 
as a result of intraoperative staging. This review presents the most significant aspects of the staging process 
and the importance of surgical treatment of early ovarian cancer.
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Ovarian cancer ranks third in incidence among 
malignant neoplasms of the female genital tract. In 
Bulgaria, its morbidity rates increases from 12,0 to 
17,7 per 100,000 women during the last 20 years. 
The disease is detected at advanced III and IV FIGO 
stages in about 70-75% of the patients. Ovarian 
cancer has the most unfavourable prognosis when 
compared to all malignancies of the female genital 
tract. According to the mortality rate for stage I-IV, 
it is the primary cause of death from genital cancer. 
In the USA, it is on the sixth place in the structure 
of female cancer incidence and on the fifth one as 
a cause of death from cancer in women after breast 
cancer, lung cancer, colorectal cancer and lymphoma. 
Despite the significant advances in surgical staging, 
multi-agent chemotherapy with platinum, new 
chemotherapeutic agents, radical cytoreduction and 
improved surgical techniques, five-year survival for 
all stages of ovarian cancer remains a constant value 
of 39% over the past 35 years. There is an increased 
incidence rate of ovarian cancer worldwide, a 
prolonged life expectancy in developed countries, 
and a lack of a common screening method. More and 
more patients are diagnosed with advanced disease, 
and five year survival in III-IV FIGO stage is 12-20%. 
The average age of patients with borderline 
tumours is approximately 46 years (1,16,17). Eighty-
to-ninety percent of ovarian cancers, including 
borderline forms, occur after the age of 40 years, 
whereas 30-40% of malignancies do after the age of 
65 years. The chance that a primary epithelial tumour 
will be of borderline or invasive malignancy in a 
patient younger than 40 years is approximately 1:10, 
however, after that age it rises to 1:3 (1,16). Less than 
1% of epithelial ovarian cancers occur before the age 
of 20 years, with two thirds of ovarian malignancies 
in such patients being germ cell tumours.
Ovarian malignancies are staged according to 
the FIGO system. It is based on findings at surgical 
exploration. A preoperative evaluation should 
exclude the presence of extraperitoneal metastases. 
The importance of the complete surgical staging 
originates the fact that subsequent treatment is 
determined by the already established stage of 
the disease. In the patients in whom exploratory 
laparotomy does not reveal any macroscopic lesions 
on inspection and palpation of intraabdominal 
space, microscopic alterations should be searched for 
(11,12). In the past, when there is no careful staging, 
the overall five-year survival of the patients at an 
apparent epithelial ovarian cancer of stage I is about 
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7. The retroperitoneal spaces should be explored 
to evaluate the pelvic and paraaortic lymph 
nodes. The retroperitoneal dissection is 
performed by incision of the peritoneum 
over the psoas muscles. This may be carried 
out only on the ipsilateral side for unilateral 
tumours. Any enlarged lymph nodes should be 
resected and promptly histologically examined. 
If no metastases are present, a formal pelvic 
lymphadenectomy should be performed.
In the patients with apparent stage I or II 
epithelial ovarian cancer, metastases occur in 3 of 
10 cases of confined tumour to the pelvis. However, 
they may present with occult metastatic disease in 
the upper abdomen or the retroperitoneal lymph 
nodes (3-15,18). In a review of the literature (2), occult 
metastases are revealed in biopsies of the diaphragm 
in 7,3% of the patients, of the omentum in 8,6%, of 
the pelvic lymph nodes in 5,9%, of the aortic lymph 
nodes in 18,1% as well as in 26,4% of peritoneal 
lavages.
The importance of the careful surgical staging 
is emphasized by the findings of a cooperative 
American study (13), in which 100 patients with 
apparent stage I and II ovarian cancer referred for 
subsequent therapy undergo an additional surgical 
staging. A total of 28% of the patients initially 
believed to be at stage I present with a higher stage 
while 43% of those believed to be at stage II present 
with more advanced lesions. As a result of additional 
surgery, 31% of the patients are upstaged and 77% 
of the cases are reclassified as having stage III of 
the disease. The histological grade is a significant 
predictor of occult metastases. Sixteen-percent of the 
patients with grade 1 are upstaged, compared with 
34% with grade 2 and 46% with grade 3.
Surgery is the primary treatment of stage I 
epithelial ovarian carcinoma. The patients should 
undergo total abdominal hysterectomy, bilateral 
salpingo-oophorectomy, and surgical staging (2,13). 
In certain cases, a unilateral oophorectomy may 
be performed. Based on operative findings and 
pathological assessment, the patients at stage I are 
divided into two categories –of low-risk and high-
risk (Table 1).
60% (2). Since then, five-year survival rates between 
90 and 100% are reported for the properly staged 
patients at stage  IA or IB (4,13).
Technique for surgical staging  
The ovarian tumour should be removed intactly, 
if possible, and examined histologically promptly. If 
the tumour is limited to the pelvis, thorough surgical 
staging should be performed involving the following 
steps (1):
1. Any free fluid, especially in the pelvic cul-de-
sac, should be cytologically examined. 
2. If there is no free liquid, peritoneal lavage 
should be done by instilling 50-100 mL of 
saline in the pelvic cul-de-sac, each paracolic 
gutter, and beneath each hemidiaphragm. The 
washing under the diaphragm can be facilitated 
by means of a rubber catheter attached to the 
syringe.
3. A systematic exploration of any intraabdominal 
surfaces and visceral organs is performed in a 
clockwise fashion from the cecum cephalad 
along the paracolic gutter and the ascending 
colon to the right kidney, the liver and 
gallbladder, the right hemidiaphragm, across 
the transverse colon to the left hemidiaphragm, 
down to the left paracolic gutter to the 
rectosigmoid colon. The small intestine should 
be inspected from Treitz’s ligament to the 
cecum.
4. Any suspicious areas of adhesions on the 
peritoneal surface should be histologically 
examined. If there are no obvious lesions, 
multiple intraperitoneal biopsies should be 
taken. Tissue of the peritoneum of the pelvic cul-
de sac, both paracolic gutters, the peritoneum 
over the bladder and the intestinal mesenteries 
should be taken for biopsy examination.
5. The diaphragm should be examined by taking 
biopsy or by scraping and obtaining the sample 
for cytological assessment. The biopsies can 
be facilitated by using the laparoscope and the 
associated biopsy instrument.
6. The omentum should be resected from the 
transverse colon by infracolic omentectomy. If 
the gastrocolic ligament is normal on palpation, 
it is not resected at all.
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Borderline tumours
The surgical resection of the primary tumour is 
the main treatment option in borderline neoplasms. 
There is no evidence that subsequent chemotherapy 
or radiation therapy improves patient’s survival. 
After a determination of a borderline tumour on a 
frozen histologic section in premenopausal patients 
who desire preservation of their ovarian function, 
they may undergo conservative surgery such as a 
unilateral oophorectomy (1,3,19). A study of patients 
with unilateral ovarian cystectomy for stage I 
borderline serous tumours (19) demonstrates that 
this conservative operation is safe, too. Relapses 
occur in 8% of the patients only, two to 18 years later 
on as the disease remains limited to the ovaries. 
These recurrences are associated with positive 
margins of the removed ovarian cyst. Thus the 
hormonal function and fertility can be preserved. For 
patients in whom an oophorectomy or cystectomy is 
performed and a borderline tumour is identified from 
the permanent histological  sample, no additional 
immediate surgery is necessary any more.
Stage I, low-grade and low-risk patterns
Abdominal hysterectomy and bilateral salpingo-
oophorectomy are appropriate treatment options for 
the patients with a thorough staging laparotomy and 
without any evidence of dissemination beyond the 
ovary. Uterus and contralateral ovary can be preserved 
in women with stage Ia, grade 1 disease who desire 
to preserve their fertility. Woman’s status should be 
dynamically monitored by periodic examinations 
and serum CA125 level determinations. In general, 
the other ovary and the uterus are removed at child 
bearing completion.
The outcome of 656 patients with early-stage 
epithelial ovarian cancer was investigated (8). No 
patients with stage Ia, grade 1 cancer remaining 
not treated die of their disease. The conclusion is 
drawn that adjuvant radiation and chemotherapy 
are unnecessary. Furthermore, the Gynecologic 
Oncology Group performs two prospective, 
randomized national cooperative trials of adjuvant 
therapy in patients with localized ovarian carcinoma 
(20). There are no significant differences between the 
patients with stage Ia and Ib, grade I of disease, given 
no chemotherapy and those treated with melphalan 
with respect to either five-year disease-free survival 
(91 versus 98%) or overall survival (94 versus 98%). 
Comprehensive staging at the time of surgical 
resection can serve to identify those patients who can 
be followed without adjuvant chemotherapy.
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